These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 21365202)

  • 41. Clozapine Monotherapy as a Treatment for Antipsychotic-Induced Tardive Dyskinesia: A Meta-Analysis.
    Mentzel TQ; van der Snoek R; Lieverse R; Oorschot M; Viechtbauer W; Bloemen O; van Harten PN
    J Clin Psychiatry; 2018 Sep; 79(6):. PubMed ID: 30257080
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tardive dyskinesia from atypical antipsychotic agents in patients with mood disorders in a clinical setting.
    Coplan J; Gugger JJ; Tasleem H
    J Affect Disord; 2013 Sep; 150(3):868-71. PubMed ID: 23726783
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Can atypical antipsychotics improve tardive dyskinesia associated with other atypical antipsychotics? Case report and brief review of the literature.
    Peritogiannis V; Tsouli S
    J Psychopharmacol; 2010 Jul; 24(7):1121-5. PubMed ID: 19395427
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Identifying Tardive Dyskinesia: Risk Factors, Functional Impact, and Diagnostic Tools.
    Saklad SR
    J Clin Psychiatry; 2020 Jan; 81(1):. PubMed ID: 31944066
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Haloperidol-Induced Preclinical Tardive Dyskinesia Model in Rats.
    Guzen FP; Cavalcanti JRLP; Cavalcanti DMLP; de Sales LGP; da Silva MSM; da Silva ANA; Pinheiro FI; de Araújo DP
    Curr Protoc Neurosci; 2019 Jun; 88(1):e68. PubMed ID: 31216395
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Role of Vesicular Monoamine Transporter 2 Inhibitors in Tardive Dyskinesia Management.
    Sreeram V; Shagufta S; Kagadkar F
    Cureus; 2019 Aug; 11(8):e5471. PubMed ID: 31641566
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC; Kane JM; Liang GS; Burke J; O'Brien CF
    Psychopharmacol Bull; 2017 Aug; 47(3):61-68. PubMed ID: 28839341
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Incidence of tardive dyskinesia and tardive dystonia in African Caribbean patients on long-term antipsychotic treatment: the Curaçao extrapyramidal syndromes study V.
    van Harten PN; Hoek HW; Matroos GE; van Os J
    J Clin Psychiatry; 2006 Dec; 67(12):1920-7. PubMed ID: 17194270
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Neuroleptic withdrawal in treatment-resistant patients with schizophrenia: tardive dyskinesia is not associated with supersensitive psychosis.
    Apud JA; Egan MF; Wyatt RJ
    Schizophr Res; 2003 Sep; 63(1-2):151-60. PubMed ID: 12892869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Atypical antipsychotic agents: a critical review.
    Worrel JA; Marken PA; Beckman SE; Ruehter VL
    Am J Health Syst Pharm; 2000 Feb; 57(3):238-55. PubMed ID: 10674777
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients.
    Spivak B; Mester R; Abesgaus J; Wittenberg N; Adlersberg S; Gonen N; Weizman A
    J Clin Psychiatry; 1997 Jul; 58(7):318-22. PubMed ID: 9269253
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pathophysiological mechanisms underlying tardive dyskinesia.
    Gerlach J
    Psychopharmacology Suppl; 1985; 2():98-103. PubMed ID: 2860666
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clozapine and tardive dyskinesia in patients with schizophrenia: A systematic review.
    Pardis P; Remington G; Panda R; Lemez M; Agid O
    J Psychopharmacol; 2019 Oct; 33(10):1187-1198. PubMed ID: 31347436
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia.
    Soares-Weiser K; Rathbone J
    Cochrane Database Syst Rev; 2006 Jan; (1):CD000459. PubMed ID: 16437425
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lurasidone-Induced Tardive Syndrome.
    Tripathi R; Reich SG; Scorr L; Guardiani E; Factor SA
    Mov Disord Clin Pract; 2019 Sep; 6(7):601-604. PubMed ID: 31538095
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Atypical antipsychotic drugs and tardive dyskinesia: relevance of D2 receptor affinity.
    Bressan RA; Jones HM; Pilowsky LS
    J Psychopharmacol; 2004 Mar; 18(1):124-7. PubMed ID: 15107196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New strategies for old problems: tardive dyskinesia (TD). Review and report on severe TD cases treated with clozapine, with 12, 8 and 5 years of video follow-up.
    Larach VW; Zamboni RT; Mancini HR; Mancini RR; Gallardo RT
    Schizophr Res; 1997 Dec; 28(2-3):231-46. PubMed ID: 9468357
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Motor symptoms of schizophrenia: is tardive dyskinesia a symptom or side effect? A modern treatment.
    Lerner V; Miodownik C
    Curr Psychiatry Rep; 2011 Aug; 13(4):295-304. PubMed ID: 21519907
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Withdrawal-emergent dyskinesia in patients with schizophrenia during antipsychotic discontinuation.
    Schultz SK; Miller DD; Arndt S; Ziebell S; Gupta S; Andreasen NC
    Biol Psychiatry; 1995 Dec; 38(11):713-9. PubMed ID: 8580223
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.
    Andrew HG
    Can J Psychiatry; 1994 Nov; 39(9 Suppl 2):S76-80. PubMed ID: 7874668
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.